611

DRUG7 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Dermatitis, AtopicEczema, AtopicHealthyNasal PolypsPolypsPulmonary Disease, Chronic Obstructive (COPD)Sinusitis

Phase 1

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

CompletedNCT04527718

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Healthy

Start: 2020-09-09End: 2021-08-13Updated: 2022-11-10

Phase 2

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Active, not recruitingNCT05865496

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Nasal Polyps, Polyps, Sinusitis

Start: 2023-06-30End: 2024-07-31Target: 90Updated: 2024-01-12

Phase 3

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

CompletedNCT06173284

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Dermatitis, Atopic

Start: 2024-01-22End: 2025-11-20Updated: 2026-01-15

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

Active, not recruitingNCT06554847

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Dermatitis, Atopic, Eczema, Atopic

Start: 2024-09-23End: 2026-08-16Target: 400Updated: 2025-07-14

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Active, not recruitingNCT06639295

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Nasal Polyps, Sinusitis

Start: 2024-11-22End: 2026-08-31Updated: 2025-12-03

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

RecruitingNCT07039669

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Pulmonary Disease, Chronic Obstructive (COPD)

Start: 2025-07-16End: 2028-11-30Target: 594Updated: 2025-11-18

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

RecruitingNCT07042126

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Dermatitis, Atopic

Start: 2025-08-05End: 2027-09-30Target: 180Updated: 2025-11-18

Related Papers

Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial

Dermatology and Therapy2025-03-091 citations